PREPARED BY: DATE PREPARED: PHONE: Nikki Swope February 23, 2021 402-471-0042

LB 30

Revision: 00

FISCAL NOTE

LEGISLATIVE FISCAL ANALYST ESTIMATE

ESTIMATE OF FISCAL IMPACT - STATE AGENCIES (See narrative for political subdivision estimates)							
	FY 202	1-22	FY 20	FY 2022-23			
	EXPENDITURES	REVENUE	EXPENDITURES REVENUE				
GENERAL FUNDS							
CASH FUNDS							
FEDERAL FUNDS							
OTHER FUNDS							
TOTAL FUNDS	See below		See below				

Any Fiscal Notes received from state agencies and political subdivisions are attached following the Legislative Fiscal Analyst Estimate.

LB30 would require that any individual or group health insurance policy or any self-funded employee benefit plan, to the extent not preemptive by federal law, limit the total amount covered individuals are required to pay for prescription insulin drugs at an amount not to exceed one hundred dollars per thirty day supply, regardless of the amount or type of insulin needed to fulfill the covered individual's prescription. This bill has an effective date of January 1, 2022.

The State of Nebraska offers six health plans, three of which divides prescription drugs into 3 tiers with an assigned corresponding deducible or copay dependent upon the type. The co-pays under these three plans are below the one hundred dollar limit as introduced by the bill; therefore there is no expected fiscal impact for these pans. The other three plans that are offered are High-Deductible Health Plans. For these plans, the cost of claims over one hundred dollars would shift to the State of Nebraska, however, the fiscal impact would be minimal based on historical data. It is estimated that the shift of the state employee's costs to the State of Nebraska Pharmacy plan would have an estimated increase in FY20-21 of \$5,000 and on-going annual costs of \$10,000. The estimated increase would have a nominal fiscal impact to the State of Nebraska's medical/pharmacy plans.

The University of Nebraska's pharmacy plan currently covers individuals' costs for insulin products at or under one hundred dollars that are on the University plan's formulary drug list. However, certain insulin drugs are not currently covered under the University plan's formulary and may cost over one hundred dollars. If the bill intends to provide coverage for these drugs that are not included in the University's formulary, the University anticipates a minimal fiscal impact of less than \$15,000.

The Department of Insurance anticipates no fiscal impact. No expected duties are expected of the Department, however, should there be any increased enforcement such duties will be absorbed by available resources.

There is no basis to disagree with these estimates.

ADMI	INISTRATIVE SERVICES	S STATE BUDGET DIVISION: REVIE	W OF AGENCY & POLT. SUB. RESPONSE			
LB: 30	AM:	AGENCY/POLT. SUB: Depart	tment of Administrative Services			
REVIEWED	BY: Neil Sullivan	DATE: 1/19/2021	PHONE: (402) 471-4179			
COMMENTS: The Department of Administrative Services estimate of minimal fiscal impact from LB 30 appears reasonable.						

ADMINISTRATIVE SERVICES STATE BUDGET DIVISION: REVIEW OF AGENCY & POLT. SUB. RESPONSE						
LB: 30	AM:	AGENCY/POLT. SUB: Univer	sity of Nebraska			
REVIEWED	BY: Neil Sullivan	DATE: 1/25/2021	PHONE: (402) 471-4179			
COMMENTS: The University of Nebraska assessment of minimal fiscal impact from LB 30 appears reasonable.						

ADMI	NISTRATIVE SERVICES	S STATE BUDGET DIVISION: REVIE	W OF AGENCY & POLT. SUB. RESPONSE			
LB: 30	AM:	AGENCY/POLT. SUB: Depart	ment of Insurance			
REVIEWED	BY: Neil Sullivan	DATE: 2/22/2021	PHONE: (402) 471-4179			
COMMENTS: The Department of Insurance assessment of no fiscal impact from LB 30 appears reasonable.						

LB ⁽¹⁾ 30					FISCAL NOTE		
State Agency OR Political S	Subdivision Name: (2)	Department of Administrative Services (DAS) – Employee Wellness & Benefits					
Prepared by: (3) Jennif	er Norris	Date Prepared: (4)	01/11/2021	Phone: (5)	402-471-4443		
F	STIMATE PROVID	DED BY STATE AGENO	CY OR POLITICAL	SUBDIVISIO	N		
	<u>FY</u> EXPENDITURES	2021-22 <u>REVENUE</u>	EXPENDIT	<u>FY 2022-</u> <u>URES</u>	- <u>23</u> <u>REVENUE</u>		
GENERAL FUNDS CASH FUNDS							
FEDERAL FUNDS REVOLVING FUNDS							
TOTAL FUNDS	See Below	<u> </u>	See Beld	<u>DW</u>			

Explanation of Estimate:

LB 30 would require, effective January 1, 2022, any self-funded employee benefit plans to the extent not preempted by federal law, which provides reimbursement for prescription insulin drugs, to limit the amount that a covered individual is required to pay for a covered prescription insulin drug no more than \$100.00 for a thirty-day supply of insulin, regardless of the amount or type of insulin needed to fill the covered individuals prescription.

The State of Nebraska offers six health plans: three with pharmacy copays that divide drugs into three tiers – WellNebraska with Incentive, WellNebraska without Incentive and Regular Health. Current member pharmacy copays for insulin for the Well/Regular plans are below the \$100 limit introduced; therefore, there is no expected fiscal impact for these plans.

There are three High Deductible Health Plans – Consumer Focus, Primary Care Select and Primary Care Standard with pharmacy costs within the deductible costs. For these plans, the cost of any claims over \$100 would shift to the State of Nebraska; therefore, there is a potential fiscal impact. Records show the average cost of an insulin prescription is \$98, thus the fiscal impact to the State for claims over \$100 is anticipated to be minimal.

Ninety percent (90%) of program membership are enrolled in the plans offering pharmacy copays with the remaining 10% in the high deductible plans.

For FY19-20, the pharmacy claims paid for the State of Nebraska health plans totaled \$48,819,000. Medical and Pharmacy Benefits for the State of Nebraska are self-insured. Any increase in claims will be reflected in the cost of premiums. The State of Nebraska pays 79% of the premiums with the teammate paying 21%.

To apply LB 30 as a monthly limit of \$100 total for all insulin prescriptions, it is estimated as an increase in in FY21-22 of \$5,000 (1/2 plan year) and \$10,000 in FY22-23. This estimated increase would have a limited fiscal impact on the State of Nebraska's medical/pharmacy plans.

BREAKD	OWN BY MAJ	OR OBJECTS O	F EXPENDITURE	
Personal Services:				
	NUMBER OF POSITIONS		2021-22	2022-23
POSITION TITLE	<u>21-22</u>	<u>21-23</u>	EXPENDITURES	EXPENDITURES
•				
Benefits				
Operating				
Travel				
Capital outlay				
Aid				
Capital improvements				
TOTAL				

LB ⁽¹⁾ 30						FISCAL NOTE	
State Agency OR Political	University of Nebraska						
Prepared by: (3) Michael Justus		Dat	te Prepared: (4)	5) 402-472-7109			
	ESTIMATE PRO	VIDED BY	STATE AGEN	CY OR POLITICAL	_SUBDIV	ISION	
	<u>E</u> EXPENDITURI	Y 2021-22 ES	REVENUE	EXPENDITU		022-23 <u>REVENUE</u>	
GENERAL FUNDS							
CASH FUNDS							
FEDERAL FUNDS							
OTHER FUNDS							
TOTAL FUNDS							
Explanation of Estimate:							
Where a potential, but state that this applies formulary, it is possible University. No fiscal impact is required.	only to drugs co e that it would e	vered by a	a plan's formula	ary. If it includes o	lrugs out	side of the University's	
P. 16 '	BREAKDO	OWN BY M	IAJOR OBJECT	S OF EXPENDITU	<u>RE</u>		
Personal Services: POSITION TI		NUMBER 21-22	OF POSITIONS 22-23	2021-22 EXPENDITU		2022-23 EXPENDITURES	
Benefits							
Operating							
Travel							
Capital outlay							
Aid							
Capital improvements							
TOTAL							

LB ⁽¹⁾ 30					FISCAL NOTE		
State Agency OR Political Subdivision Name	. (2) Insuran	Insurance					
Prepared by: (3) Thomas Green	Date l	Prepared: (4) 2	/19/2021	Phone: (5)	402-471-4650		
ESTIMATE PRO	OVIDED BY ST	ATE AGENCY	OR POLITICAL	SUBDIVISIO	ON		
<u>EXPENDITU</u>	<u>FY 2021-22</u> (<u>RES</u> <u>F</u>	<u>REVENUE</u>	<u>EXPENDITI</u>	<u>FY 2022</u> URES	2-23 REVENUE		
GENERAL FUNDS							
CASH FUNDS							
FEDERAL FUNDS							
OTHER FUNDS		_					
TOTAL FUNDS							
Explanation of Estimate:							
required to pay for covered prescript dollars per 30 day supply. The Department anticipates no fisca Department, however, should there is duties will be absorbed by existing research.	I impact as a r be any increas esources.	esult of LB 30. ed enforcemen	No increased on requirements	duties are e as a result	expected of the		
Personal Services:	<u>DOWN BY MA.</u>	JOR OBJECTS (<u>OF EXPENDITU</u>	<u>RE</u>			
POSITION TITLE	NUMBER OF 21-22	F POSITIONS 22-23	2021-29 EXPENDIT		2022-23 EXPENDITURES		
Benefits							
Operating							
Travel			-				
Capital outlay			<u></u>				
Aid							
Capital improvements							
TOTAL							